Pharmacoepidemiological research using French reimbursement databases: yes we can!
Identifieur interne : 003044 ( Main/Exploration ); précédent : 003043; suivant : 003045Pharmacoepidemiological research using French reimbursement databases: yes we can!
Auteurs : Karin Martin-Latry [France] ; Bernard Bégaud [France]Source :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2010-03.
English descriptors
- Teeft :
- Absolute contraindications, Alzheimer disease, Ambulatory care, Arthritis rheum, Begaud, Begaud figure, Buprenorphine, Cadeus study, Chronic diseases, Clin, Clin epidemiol, Clin pharmacol, Commission nationale informatique, Concerns drugs, Copyright, Database, Diabetes, Diabetes metab, Drug alcohol, Drug prescriptions, Drug safety, Drug utilization, Drugs contraindicated, Entred study, Epidemiol, Epidemiol sante publique, February, French databases, French health system, French population, French region, French reimbursement databases, General population, General practitioners, General scheme, Guideline, Health authorities, Health fund, Health insurance, Health insurance database, Health insurance fund, Health insurance system, Health insurance systems, Health professionals, Health services, Health system, Hospital data, Inhibitor, John wiley sons, Joint bone spine, Main insurance schemes, Main reimbursement databases, Maladie, Medical acts, Medical reimbursement database, Medication, Metab, Metropolitan france, National guidelines, Other studies, Outpatient prescriptions, Pharmaceutical form, Pharmacoepidemiol, Pharmacoepidemiol drug, Pharmacoepidemiological, Pharmacoepidemiological research, Pharmacoepidemiological studies, Pharmacoepidemiology, Pharmacol, Potential drug interactions, Prat organ soins, Pregnant women, Prescription, Prescription date, Presse, Psychotropic drugs, Psychotropic medications, Pubmed, Recent trends, Reimbursement, Reimbursement claim, Reimbursement data, Reimbursement databases, Relevant studies, Rheumatoid arthritis, Securite sociale, Southeastern france, Study characteristics, Study patterns, Suppl, Therapie, Third generation, Unique number, Universite victor segalen bordeaux, Vital status, Weill.
Abstract
To describe the reimbursement databases available in France for pharmacoepidemiological research and their use.
France has a publicly funded health system that systematically covers the population. Within this system, three main insurance schemes provide health services to citizens in France and each have their own reimbursement database. Together these three databases cover almost 97% of the French population (respectively for 54.5, 3.6, and 3.3 million individuals, and a total of 61.4 million individuals). Data in these concern patients, prescribers, all the medical acts reimbursed, prescription and undertaking of laboratory tests (but without results), private hospital data, partial public hospital data and vital status. Their use is regulated but access is free and the data are anonymous. PubMed and Scopus were searched for relevant studies published from January 1988 to June 2009.
110 published studies were included. The topics and the study characteristics were extremely wide‐ranging. The studies assessed patterns of drug use, have tested interventions, supported or improved prescribing practices, tested compliance with the French governmental Health guidelines, assessed physicians' prescribing practices and performed economic and cost‐effectiveness assessments. The number of articles published increased greatly between 2002 and 2003.
The French reimbursement databases were greatly used over the last 20 years. They can provide data on exposure to drugs and can be used to study patterns of drug utilization although their limitations must be considered. Copyright © 2010 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/pds.1912
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000633
- to stream Istex, to step Curation: 000628
- to stream Istex, to step Checkpoint: 000806
- to stream Main, to step Merge: 003101
- to stream Main, to step Curation: 003044
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacoepidemiological research using French reimbursement databases: yes we can!</title><author><name sortKey="Martin Atry, Karin" sort="Martin Atry, Karin" uniqKey="Martin Atry K" first="Karin" last="Martin-Latry">Karin Martin-Latry</name></author><author><name sortKey="Begaud, Bernard" sort="Begaud, Bernard" uniqKey="Begaud B" first="Bernard" last="Bégaud">Bernard Bégaud</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1C1B0836CB7AEC4F17A4DA31FF60429ED6270D2A</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/pds.1912</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-P3NN3V0Q-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000633</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000633</idno><idno type="wicri:Area/Istex/Curation">000628</idno><idno type="wicri:Area/Istex/Checkpoint">000806</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000806</idno><idno type="wicri:doubleKey">1053-8569:2010:Martin Atry K:pharmacoepidemiological:research:using</idno><idno type="wicri:Area/Main/Merge">003101</idno><idno type="wicri:Area/Main/Curation">003044</idno><idno type="wicri:Area/Main/Exploration">003044</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacoepidemiological research using French reimbursement databases: yes we can!<ref type="note" target="#fn1"></ref></title><author><name sortKey="Martin Atry, Karin" sort="Martin Atry, Karin" uniqKey="Martin Atry K" first="Karin" last="Martin-Latry">Karin Martin-Latry</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Département de Pharmacologie, Université Victor Segalen Bordeaux 2, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Inserm U 657, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>CHU, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Correspondence address: Inserm U 657, Case 121, Université Victor Segalen Bordeaux 2, 146, rue Léo Saignat, 33076 Bordeaux</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Begaud, Bernard" sort="Begaud, Bernard" uniqKey="Begaud B" first="Bernard" last="Bégaud">Bernard Bégaud</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Département de Pharmacologie, Université Victor Segalen Bordeaux 2, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Inserm U 657, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>CHU, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="256">256</biblScope><biblScope unit="page" to="265">265</biblScope><biblScope unit="page-count">10</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2010-03">2010-03</date></imprint><idno type="ISSN">1053-8569</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Absolute contraindications</term><term>Alzheimer disease</term><term>Ambulatory care</term><term>Arthritis rheum</term><term>Begaud</term><term>Begaud figure</term><term>Buprenorphine</term><term>Cadeus study</term><term>Chronic diseases</term><term>Clin</term><term>Clin epidemiol</term><term>Clin pharmacol</term><term>Commission nationale informatique</term><term>Concerns drugs</term><term>Copyright</term><term>Database</term><term>Diabetes</term><term>Diabetes metab</term><term>Drug alcohol</term><term>Drug prescriptions</term><term>Drug safety</term><term>Drug utilization</term><term>Drugs contraindicated</term><term>Entred study</term><term>Epidemiol</term><term>Epidemiol sante publique</term><term>February</term><term>French databases</term><term>French health system</term><term>French population</term><term>French region</term><term>French reimbursement databases</term><term>General population</term><term>General practitioners</term><term>General scheme</term><term>Guideline</term><term>Health authorities</term><term>Health fund</term><term>Health insurance</term><term>Health insurance database</term><term>Health insurance fund</term><term>Health insurance system</term><term>Health insurance systems</term><term>Health professionals</term><term>Health services</term><term>Health system</term><term>Hospital data</term><term>Inhibitor</term><term>John wiley sons</term><term>Joint bone spine</term><term>Main insurance schemes</term><term>Main reimbursement databases</term><term>Maladie</term><term>Medical acts</term><term>Medical reimbursement database</term><term>Medication</term><term>Metab</term><term>Metropolitan france</term><term>National guidelines</term><term>Other studies</term><term>Outpatient prescriptions</term><term>Pharmaceutical form</term><term>Pharmacoepidemiol</term><term>Pharmacoepidemiol drug</term><term>Pharmacoepidemiological</term><term>Pharmacoepidemiological research</term><term>Pharmacoepidemiological studies</term><term>Pharmacoepidemiology</term><term>Pharmacol</term><term>Potential drug interactions</term><term>Prat organ soins</term><term>Pregnant women</term><term>Prescription</term><term>Prescription date</term><term>Presse</term><term>Psychotropic drugs</term><term>Psychotropic medications</term><term>Pubmed</term><term>Recent trends</term><term>Reimbursement</term><term>Reimbursement claim</term><term>Reimbursement data</term><term>Reimbursement databases</term><term>Relevant studies</term><term>Rheumatoid arthritis</term><term>Securite sociale</term><term>Southeastern france</term><term>Study characteristics</term><term>Study patterns</term><term>Suppl</term><term>Therapie</term><term>Third generation</term><term>Unique number</term><term>Universite victor segalen bordeaux</term><term>Vital status</term><term>Weill</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">To describe the reimbursement databases available in France for pharmacoepidemiological research and their use.</div><div type="abstract">France has a publicly funded health system that systematically covers the population. Within this system, three main insurance schemes provide health services to citizens in France and each have their own reimbursement database. Together these three databases cover almost 97% of the French population (respectively for 54.5, 3.6, and 3.3 million individuals, and a total of 61.4 million individuals). Data in these concern patients, prescribers, all the medical acts reimbursed, prescription and undertaking of laboratory tests (but without results), private hospital data, partial public hospital data and vital status. Their use is regulated but access is free and the data are anonymous. PubMed and Scopus were searched for relevant studies published from January 1988 to June 2009.</div><div type="abstract">110 published studies were included. The topics and the study characteristics were extremely wide‐ranging. The studies assessed patterns of drug use, have tested interventions, supported or improved prescribing practices, tested compliance with the French governmental Health guidelines, assessed physicians' prescribing practices and performed economic and cost‐effectiveness assessments. The number of articles published increased greatly between 2002 and 2003.</div><div type="abstract">The French reimbursement databases were greatly used over the last 20 years. They can provide data on exposure to drugs and can be used to study patterns of drug utilization although their limitations must be considered. Copyright © 2010 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Martin Atry, Karin" sort="Martin Atry, Karin" uniqKey="Martin Atry K" first="Karin" last="Martin-Latry">Karin Martin-Latry</name></region><name sortKey="Begaud, Bernard" sort="Begaud, Bernard" uniqKey="Begaud B" first="Bernard" last="Bégaud">Bernard Bégaud</name><name sortKey="Begaud, Bernard" sort="Begaud, Bernard" uniqKey="Begaud B" first="Bernard" last="Bégaud">Bernard Bégaud</name><name sortKey="Begaud, Bernard" sort="Begaud, Bernard" uniqKey="Begaud B" first="Bernard" last="Bégaud">Bernard Bégaud</name><name sortKey="Martin Atry, Karin" sort="Martin Atry, Karin" uniqKey="Martin Atry K" first="Karin" last="Martin-Latry">Karin Martin-Latry</name><name sortKey="Martin Atry, Karin" sort="Martin Atry, Karin" uniqKey="Martin Atry K" first="Karin" last="Martin-Latry">Karin Martin-Latry</name><name sortKey="Martin Atry, Karin" sort="Martin Atry, Karin" uniqKey="Martin Atry K" first="Karin" last="Martin-Latry">Karin Martin-Latry</name><name sortKey="Martin Atry, Karin" sort="Martin Atry, Karin" uniqKey="Martin Atry K" first="Karin" last="Martin-Latry">Karin Martin-Latry</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003044 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003044 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1C1B0836CB7AEC4F17A4DA31FF60429ED6270D2A
|texte= Pharmacoepidemiological research using French reimbursement databases: yes we can!
}}
| This area was generated with Dilib version V0.6.33. |  |